Cancer metabolism as a therapeutic target

ONCOLOGY (United States)

Volumn 27, Issue 5, 2013, Pages

  Batra, Surabhi ^a   Adekola, Kehinde U A ^a   Rosen, Steven T ^a   Shanmugam, Mala ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Ann and Robert H Lurie Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 PHOSPHOFRUCTO 2 KINASE; ANTINEOPLASTIC AGENT; BORTEZOMIB; BROMOPYRUVIC ACID; DICHLOROACETIC ACID; GLUCOSE TRANSPORTER; INDINAVIR; METFORMIN; PHOSPHOGLYCERATE DEHYDROGENASE; RITONAVIR; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ASTROCYTOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; CHEMOSENSITIVITY; CHEMOSENSITIZATION; DIETARY INTAKE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; EPIGENETICS; GENETIC DISORDER; GENETIC HETEROGENEITY; GLIOBLASTOMA; GLUCOSE INTAKE; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METABOLIC ACIDOSIS; METABOLIC DISORDER; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SURVIVAL TIME; TUMOR CELL; TUMOR VASCULARIZATION;

EID: 84877760613     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
3. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011;27:441-64.
4. Warburg O. On the origin of cancer cells. Science. 1956;123: 309-14.
5. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006;9:425-34.
6. Le A, Cooper CR, Gouw AM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Nat Acad Sci. 2010;107:2037-42.
7. Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007;11:37-51.
8. Vallejo CG, Cruz-Bermúdez A, Clemente P, et al. Evaluation of mitochondrial function and metabolic reprogramming during tumor progression in a cell model of skin carcinogenesis. Biochimie. 2013 Jan 22. [Epub ahead of print]
9. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Nat Acad Sci. 2007;104:19345-50.
10. Koppenol W H, Bounds PL, Dang CV. Otto Warburgs contributions to current concepts of cancer metabolism. Nature Rev Cancer. 2011;11:325-37.
11. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21:297-308.
12. Cooper GM, Hausman RE. The cell. ASM Press; Washington, DC, 2000.
13. Park HJ, Lyons JC, Ohtsubo T, Song CW. Acidic environment causes apoptosis by increasing caspase activity. Br J Cancer. 1999;80:1892.
14. Williams AC, Collard TJ, Paraskeva C. An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carinoma cell lines: Implications for clonal selection during colorectal carcinogenesis. Oncogene. 1999;18:3199-204.
15. Casciari JJ, Sotirchos SV, Sutherland RM. Variations in tumor cell growth rates and metabolism with oxygen concentration, glucose concentration, and extracellular pH. J Cell Physiol. 2005;151:386-94.
16. Gatenby RA, Gawlinski ET. The glycolytic phenotype in carcinogenesis and tumor invasion insights through mathematical models. Cancer Res. 2003;63:3847-54.
17. Fujiwara S, Kawano Y, Yuki H, et al. PDK1 inhibition is a novel therapeutic target in multiple myeloma. Br J Cancer. 2012;108:170-8.
18. Osthus RC, Shim H, Kim S, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem. 2000;275:21797-800.
19. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nature Rev Cancer. 2008;8:705-13.
20. Lu CW, Lin SC, Chen KF, et al. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem. 2008;283:28106-14.
21. Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452:230-3.
22. Mathupala SP, Ko YH, Pedersen PL. Hexokinase II: cancers double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene. 2006;25:4777-86.
23. Samudio I, Fiegl M, McQueen T, et al. The Warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. Cancer Res. 2008;68: 5198-205.
24. Danial NN, Gramm CF, Scorrano L, et al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature. 2003;424:952-6.
25. Rathmell JC, Fox CJ, Plas DR, et al. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol. 2003;23:7315-28.
26. Castellani M, Carletto M, Baldini L, et al. The prognostic value of F-18 fluorodeoxyglucose bone marrow uptake in patients with recent diagnosis of multiple myeloma: a comparative study with Tc-99m sestamibi. Clin Nucl Med. 2010;35:1.
27. Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989-95.
28. Bartel TB, Haessler J, Brown TL, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068-76.
29. Safdie F, Brandhorst S, Wei M, et al. Fasting enhances the response of glioma to chemo- and radiotherapy. PloS One. 2012;7:e44603.
30. Lee C, Raffaghello L, Brandhorst S, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med. 2012;4:124-27.
31. Pedersen PL, Mathupala S, Rempel A, et al. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta. 2002;1555:14-20.
32. Atsumi T, Chesney J, Metz C, et al. High expression of inducible 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res. 2002;62:5881-7.
33. Grassian AR, Metallo CM, Coloff JL, et al. Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferation. Sci Signal. 2011;25:1716.
34. Goldberg MS, Sharp PA. Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J Exp Med. 2012;209:217-24.
35. Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452:230-3.
36. Yang W, Zheng Y, Xia Y, et al. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nature Cell Biol. 2012;14:1295-304.
37. Berruti A, Bitossi R, Gorzegno G, et al. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. J Clin Oncol. 2002;20:4150-9.
38. Dearling JL, Qureshi U, Begent RH, Pedley RB. Combining radioimmunotherapy with antihypoxia therapy 2-deoxy-D-glucose results in reduction of therapeutic efficacy. Clin Cancer Res. 2007;13:1903-10.
39. Cao X, Bloomston M, Zhang T, et al. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. Clin Cancer Res. 2008;14:1831-9.
40. Nakashima RA, Mangan PS, Colombini M, Pedersen PL. Hexokinase receptor complex in hepatoma mitochondria: evidence from N, N-dicyclohexlycarbodiimide-labeling studies for the involvement of the pore-forming protein VDAC. Biochemistry. 1986;25:1015-21.
41. Chaneton B, Hillmann P, Zheng L, et al. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature. 2012;491:458-62.
42. Locasale JW, Grassian AR, Melman T, et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet. 2011;43:869-74.
43. Sheng SL, Liu JJ, Dai YH, et al. Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma. FEBSJ. 2012;279:3898-910.
44. Adekola K, Rosen ST, Shanmugam M. Glucose transporters in cancer metabolism. Curr Opin Oncol. 2012;24:650-4.
45. Chan DA, Sutphin PD, Nguyen P, et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Translat Med. 2011; 3:94-70.
46. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. Sci Signal. 2000;275:20251.
47. Vyas AK, Koste, JC, Tzekov A, Hruz PW. Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice. J Biol Chem. 2010;285:36395-400.
48. McBrayer SK, Cheng JC, Singhal S, et al. Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy. Blood. 2012;119:4686-97.
49. Kovaevi K, Morris HP. The role of glutamine in the oxidative metabolism of malignant cells. Cancer Res. 1972;32:326-33.
50. Yang C, Sudderth J, Dang T, et al. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 2009;69: 7986-93.
51. Reynolds MR, Lane AN, Robertson B, et al. Control of glutamine metabolism by the tumor suppressor Rb. Oncogene. 2013 Jan 28. [Epub ahead of print]
52. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29:254-8.
53. Brunmair B, Staniek K, Gras F, et al. Thiazo lidinediones, like metformin, inhibit respiratory complex IA common mechanism contributing to their antidiabetic actions? Diabetes. 2004;53:1052-9.
54. Memmott RM, Mercado JR, Maier CR, et al. Metformin prevents tobacco carcinogeninduced lung tumorigenesis. Cancer Prev Res. 2010;3:1066-76.
55. Anisimov VN, Egormin PA, Piskunova TS, et al. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle. 2010;9:188-97.
56. Deng XS, Wang S, Deng A, et al. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle. 2012;11:367-76.
57. Longo VD, Fontana L. Calorie restriction and cancer prevention: metabolic and molecular mechanisms. Trends Pharm Sci. 2010;31:89-98.